Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04085159
Recruitment Status : Recruiting
First Posted : September 11, 2019
Last Update Posted : September 18, 2019
Sponsor:
Information provided by (Responsible Party):
Shenzhen Geno-Immune Medical Institute

Brief Summary:
The primary objective of this study is to verify the safety of antigen-specific T cells (CAR-T) and engineered immune effector cytotoxic T cells (EIE) modified by immunoregulatory genes and immune modified dendritic cell vaccine (DCvac) in the treatment of neurofibromatosis or schwannoma.

Condition or disease Intervention/treatment Phase
Cancer Biological: Antigen-specific T cells CART/CTL and DCvac Phase 1 Phase 2

Detailed Description:

Neurofibromatosis (NF) is caused by a genetic change that tends to develop benign tumors around nerves. NF is a lifelong condition that affects all populations equally, regardless of gender or ethnicity. Neurofibromatosis has been classified into three distinct types: NF1, NF2, and schwannomatosis. The hallmark tumors seen in NF2 are vestibular schwannomas, formerly known as acoustic neuromas. Vestibular schwannomas are benign tumors made up of abnormal Schwann cells, which are the cells that give the nerves the lining and insulation needed to conduct information. Vestibular schwannomas can cause hearing loss in one or both ears, depending on whether the tumors are unilateral or bilateral.

Schwannomatosis is the same type of tumor as that of NF2 patients. Tumors are all related to Schwann cells. There is no cure for NF or schwannomatosis. Surgery is the only clinical method at present, and no drugs have been proved to be effective in the treatment of these tumors.

Adoptive immunotherapy based on cytotoxic T lymphocytes reactive with specific antigens has proven to be effective. In vitro induction of tumor antigen-specific immune cells and engineering of target specific immune cells have great potential for cancer eradication. If CAR-T/CTL immunotherapy is effective, it is expected that Neurofibromatosis or Schwannomatosis tumors should shrink or disappear completely. However, the minimal residual tumor cells or cancer stem cells may exist and cause relapse to other tissues and organs. Follow-up immunotherapy must focus on enhancing the anti-tumor immunity. Therefore, this protocol includes follow-up application of DCvac to prevent recurrence. This study proposes a novel protocol of immunotherapy to evaluate the safety and effectiveness of targeting tumor antigens in patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Immunotherapy Targeting Neurofibromatosis or Schwannomatosis
Actual Study Start Date : September 1, 2019
Estimated Primary Completion Date : January 31, 2021
Estimated Study Completion Date : December 31, 2022


Arm Intervention/treatment
Experimental: CART/CTL/DCvac cells to treat cancer Biological: Antigen-specific T cells CART/CTL and DCvac
Antigen-specific T cells CART/CTL and DCvac cells to treat cancer




Primary Outcome Measures :
  1. Percentage of adverse effects after CART/CTL/DCvac cells injection [ Time Frame: up to one month ]
    To assess the safety of autologous CART/CTL/DCvac cells in patients. The percentage of patients who have adverse effects will be evaluated by using the NCI CTCAE V4.0 criteria.


Secondary Outcome Measures :
  1. Rate of successful CART/CTL/DCvac cell production [ Time Frame: up to one month ]
    The percentage of successful CART/CTL/DCvac cell generation, which is based on products which pass the safety test after standard culture procedures, viable for at least one preparation, will be evaluated.

  2. Ability of CART/CTL/DCvac cells to induce anti-cancer reaction [ Time Frame: after 1 month from CART/CTL/DCvac cells infusion until 12 months after infusion ]
    measurement of concentration of tumor associated markers

  3. Ability of CART/CTL/DCvac cells for anti-tumor reaction [ Time Frame: after 1 month from CART/CTL/DCvac cells infusion until 24 months after infusion ]
    Objective response (complete response (CR) + partial response (PR)) was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written, informed consent obtained prior to any study-specific procedures.
  2. Diagnosis of neurofibromatosis, or schwannomatosis
  3. The results of immune staining of the patient's cancer specimens positive for any one or more of a list of tumor-associated antigens.
  4. Age ≥ 1 years
  5. At least one volumetrically measurable and ≥ 0.5 cc NF-related tumor (schwannoma, ependymoma, meningioma - histological confirmation not required) with radiographic evidence of progression (either as unequivocal progression on conventional MRI, or a >10% volume increase by 3D volumetrics) over the past ≤12 months, designated as the primary target tumor OR Volumetrically measurable and ≥ 0.5 cc VS with ipsilateral progressive hearing loss over the past ≤12 months, designated as the primary target tumor.
  6. Progressive Hearing Loss Criteria for Enrollment: Audiogram showing drop in pure tone average (PTA) of 10dB HL at ≥ 2 nonconsecutive or consecutive frequencies or drop in speech discrimination score (SDS) below the 95% critical difference threshold, compared to previous audiogram ≤ 1 year prior.
  7. Karnofsky/Lansky performance status (PS) 50-100%. Note: Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
  8. Any neurologic deficits must be stable for ≥ 1 week.
  9. Adequate bone marrow reserve with

    • absolute neutrophil count (ANC) ≥ 1000/mm3.
    • Platelets ≥100,000/mm3.
  10. Adequate renal and hepatic function with

    • Serum creatinine ≤ 2 x upper limit of normal (ULN).
    • Serum bilirubin ≤ 2 x ULN.
    • aspartate aminotransferase (AST)/ALT ≤ 2 x ULN.
    • Alkaline phosphatase ≤ 5 x ULN.
    • Serum bilirubin 2.0 is acceptable in the setting of known Gilbert's syndrome.

Exclusion Criteria:

  1. The results of immune staining of the patient's tumor-associated antigens are all negative.
  2. Participation in any other cell therapy protocols within one year.
  3. Current or recent treatment (within the 28-day period prior to Day 0) with another investigational drug.
  4. Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study.
  5. Pregnant or lactating females.
  6. Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases.
  7. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:

    • Symptomatic congestive heart failure of New York heart Association Class III or IV
    • unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease
    • severely impaired lung function as defined as spirometry and DLCO that is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest on room air
    • uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN (Note: Optimal glycemic control should be achieved before starting trial therapy.)
    • active (acute or chronic) or uncontrolled severe infections
    • liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class C).
  8. Inadequate bone marrow function:

    • Absolute neutrophil count < 1.0 x 10e9/L.• Platelet count < 100 x 10e9/L.
    • Hb < 9 g/dL.
  9. Inadequate liver and renal function:

    • Serum (total) bilirubin > 1.5 x ULN.
    • AST & ALT > 2.5 x ULN (> 5 x ULN in patients with liver metastases).
    • Alkaline phosphatase > 2.5 x ULN (or > 5 x ULN in case of liver metastases or > 10 x ULN in case of bone metastases).
    • Serum creatinine >2.0 mg/dl (> 177 μmol/L).
    • Urine dipstick for protein uria should be < 2+. Patients with ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo 24 hour urine collection and must demonstrate < 1 g of protein/24 hr.
  10. Subject infected with HIV (HIV antibody positive), Treponema pallidum antibody positive or TB culture positive.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04085159


Contacts
Layout table for location contacts
Contact: Lung-Ji Chang, PhD 86-075586725195 c@szgimi.org

Locations
Layout table for location information
China, Guangdong
Shenzhen Geno-immune Medical Institute Recruiting
Shenzhen, Guangdong, China, 518000
Contact: Lung-Ji Chang, PhD    86-075586725195    c@szgimi.org   
Department of Neurosurgery, Shenzhen Hospital, Southern Medical University Recruiting
Shenzhen, Guangdong, China, 518100
Contact: Jie Mao, MD    +86 13955340100      
Contact: Dinglan Wu, MD    +86 13823166012      
Sponsors and Collaborators
Shenzhen Geno-Immune Medical Institute

Layout table for additonal information
Responsible Party: Shenzhen Geno-Immune Medical Institute
ClinicalTrials.gov Identifier: NCT04085159    
Other Study ID Numbers: GIMI-IRB-19006
First Posted: September 11, 2019    Key Record Dates
Last Update Posted: September 18, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Shenzhen Geno-Immune Medical Institute:
immunotherapy T cell cancer gene therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Neurofibromatoses
Neurofibromatosis 1
Neurofibroma
Nerve Sheath Neoplasms
Neoplasms, Nerve Tissue
Neoplasms by Histologic Type
Neoplasms
Neoplastic Syndromes, Hereditary
Neurocutaneous Syndromes
Nervous System Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Peripheral Nervous System Diseases
Neuromuscular Diseases
Peripheral Nervous System Neoplasms
Nervous System Neoplasms
Immunologic Factors
Physiological Effects of Drugs